Key result
Fulminant myocarditis management relies on early advanced diagnostics, tailored inotropes, temporary MCS, and targeted immunotherapy.
Why the study?
Fulminant myocarditis is a life-threatening syndrome with diverse etiologies causing rapidly progressive cardiogenic shock, malignant arrhythmias, and multiorgan dysfunction that requires integrated critical care management and a practical intensive care approach.
Provides a practical critical care framework for managing acute fulminant myocarditis through early recognition, mechanical circulatory support (such as VA-ECMO), and etiology-directed immunomodulatory therapy.
Answers are grounded in this paper and cite their sources.
May inform ICU management of fulminant myocarditis; leaves open need for prospective validation of VA-ECMO and immunomodulation.
Fulminant myocarditis is a life-threatening inflammatory cardiac syndrome characterized by severe myocardial injury and abrupt deterioration of cardiac function, leading to rapidly progressive cardiogenic shock. Patients often require intravenous vasoactive therapy and/or temporary mechanical circulatory support to maintain systemic perfusion and prevent multiorgan failure. Although frequently preceded by a viral prodrome and affecting young and healthy individuals, fulminant myocarditis encompasses diverse etiologies, including immune-mediated and toxin-related subtypes, with major implications for diagnosis and treatment. Optimal management relies on early recognition, prompt admission to specialized cardiac intensive care units, and rapid access to advanced diagnostics, including endomyocardial biopsy and cardiac magnetic resonance imaging, to confirm myocardial inflammation, exclude ischemic disease, and guide etiology-directed therapy. Hemodynamic stabilization requires tailored use of vasopressors and inotropes while minimizing catecholamine-related arrhythmias and myocardial oxygen demand. For refractory shock, early escalation to temporary mechanical circulatory support, most commonly venoarterial extracorporeal membrane oxygenation, is central to restore perfusion and provide a bridge to recovery or advanced therapy. Because fulminant myocarditis frequently involves malignant arrhythmias and multiorgan dysfunction, integrated critical care management is essential. This review summarizes a practical intensive care approach to fulminant myocarditis, emphasizing early diagnosis, individualized hemodynamic and device-based support, multiorgan management, and phenotype-driven immunomodulatory treatment strategies.
No takes yet. Share an insight, caveat, or question.
Bottiroli et al. (2026) conducted a review in Acute fulminant myocarditis with cardiogenic shock. Critical care management including vasoactive therapy, temporary mechanical circulatory support (e.g., VA-ECMO), and phenotype-driven immunomodulatory treatment was evaluated. Integrated critical care management of fulminant myocarditis relies on early diagnosis via biopsy/CMR, tailored vasoactive and mechanical circulatory support (e.g., VA-ECMO), and targeted therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: